RecruitingPhase 2NCT05806931

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Sequential Combined TAS-102 and Oxaliplatin Alternating With TAS-102 and Irinotecan (Sequential TASOXIRI) With Bevacizumab for Late-Line Metastatic Colorectal Cancer

Sponsor

Rutgers, The State University of New Jersey

Enrollment

50 participants

Start Date

May 17, 2023

Study Type

INTERVENTIONAL

Conditions

Colon Cancer Rectal Cancer

Summary

This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing an alternating chemotherapy strategy for people with advanced colorectal cancer (stage IV) that has already stopped responding to standard treatments. The approach rotates between two chemo combinations to try to avoid drug resistance. **You may be eligible if...** - You have stage IV colon or rectal cancer confirmed by biopsy - Your cancer has progressed after standard treatments including 5-FU, irinotecan, oxaliplatin, and appropriate antibody therapies - You have had all recommended standard treatments (or could not tolerate them due to side effects) - You are in adequate overall health to receive further chemotherapy **You may NOT be eligible if...** - You have not yet received standard first- or second-line treatments - Your cancer cannot be confirmed by tissue analysis - You are too unwell to receive chemotherapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTAS-102, oxaliplatin, irinotecan with bevacizumab

Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.